NEW YORK--(BUSINESS WIRE)--The Rosen Law Firm, P.A., a global investor rights law firm, announces it is investigating potential securities claims on behalf of investors of Cellular Biomedicine Group Inc. (NASDAQ: CBMG) resulting from allegations that Cellular Biomedicine Group may have issued materially misleading business information to the investing public.
On April 7, 2015, Seeking Alpha published a report on Cellular Biomedicine Group, which asserts that: (i) it has achieved an unsustainable valuation with paid stock promotion; (ii) its “CAR-T” technology has experienced patient deaths and is worthless; (iii) its founders face multiple allegations of dishonesty and are responsible for an alleged illegal offshore stem cell clinic; and (iv) it has multiple accounting and financial integrity issues. On this news, shares of Cellular Biomedicine Group fell sharply during intraday trading on April 7, 2015.
The Rosen Law Firm is preparing a class action lawsuit to recover losses suffered by Cellular Biomedicine Group investors. If you purchased shares of Cellular Biomedicine Group on or before April 7, 2015, please visit the website at http://rosenlegal.com/cases-569.html for more information. You may also contact Phillip Kim, Esq. or Kevin Chan, Esq. of The Rosen Law Firm toll free at 866-767-3653 or via email at email@example.com or firstname.lastname@example.org.
The Rosen Law Firm represents investors throughout the globe, concentrating its practice in securities class actions and shareholder derivative litigation.
Attorney Advertising. Prior results do not guarantee a similar outcome.